Invokana win in kidney patients could help J&J right the SGLT2 ship
Johnson & Johnson might just have a way to buoy its sinking Invokana sales. The diabetes drug put up data in chronic kidney patients showing it could stall disease progression and fend off cardiovascular problems, too, setting it up for a new FDA nod. In a phase 3 study of type 2 diabetes patients with… Read More »